Shares of Agile Therapeutics, Inc. (NASDAQ:AGRX) in the Tank After Law Offices of Howard G. Smith Commence Investigation on Behalf of Investors

Specialty pharmaceutical company that focuses on the development and commercialization of prescription contraceptive products for women, Agile Therapeutics, Inc. (NASDAQ:AGRX), is under investigation for potential violation of federal securities laws.

BENSALEM, Pa.–(BUSINESS WIRE)–

Law Offices of Howard G. Smith announces an investigation on behalf of investors of Agile Therapeutics, Inc. (“Agile” or the “Company”) (NASDAQ: AGRX) concerning the Company and its officers’ potential violation of federal securities laws.

Agile is a specialty pharmaceutical company that focuses on the development and commercialization of prescription contraceptive products for women.

On January 3, 2017, Agile disclosed statistical information pertaining to its Phase 3 SECURE study analyzing the Company’s combined hormonal contraceptive patch Twirla. The study, which was initiated at the request of the FDA, comes after the FDA rejected Agile’s initial marketing application back in 2013. The Company cited “positive top-line results” in the study, yet reported that almost 2% of subjects experienced “serious adverse events” including “deep vein thrombosis, pulmonary embolism, gallbladder disease, ectopic pregnancy and depression.” Additionally, 51.4% of subjects opted to discontinue the study.

On this news, Agile stock fell nearly 64% during intraday trading on January 4, 2017.

If you purchased Agile securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Original Source

agile-therapeutics-graph

Agile Therapeutics, Inc. (NASDAQ:AGRX) shares are trading -47.40% on the news and in the range of $1.82 – 2.94 during the current trading session.  When taking a look at which direction the stock might be headed, investors often look to brokerage analysts who cover the stock.  Sell-side research firms on Wall Street currently have a consensus one-year price target of $16.20 on the stock.  This is according to brokerage analysts polled by Thomson Reuters First Call.

Are Shares of Agile Therapeutics, Inc. (NASDAQ:AGRX) Ready to Explode?  Sign up to our Newsletter to be the First to Know

Sign up to get our Free Penny Stock Picks Before the Street!

Sell-side analysts are projecting earnings per share of $-0.30 for the next fiscal quarter.  For the current year, analysts are predicting earnings of $-1.15 per share according to First Call.

In looking at where the stock is trading on a technical level, the stock is trading -60.58% away from its 50-day moving average of $6.67.  Based on the most recent available data, the equity is -73.70% off of its 52-week high of $10.00 and +44.51% away from its 52-week low which is $1.82.

Today, the stock opened at $1.93 and the last bid at the time of writing stood at $2.63.  During the session thus far, the equity dipped down to $1.82 and touched $2.94 as the high point.  Agile Therapeutics, Inc. (NASDAQ:AGRX) has a market cap of $75.63M and has seen an average daily volume of 101,251 over the past three months.

Sign Up to Receive Breaking Alerts on Stocks That Are Primed to Make a Run in the Bar Below. 

Sign up to get our Free Penny Stock Picks Before the Street!

Disclaimer: Nothing contained in this publication is intended to constitute legal, tax, securities, or investment advice, nor an opinion regarding the appropriateness of any investment, nor a solicitation of any type. The general information contained in this publication should not be acted upon without obtaining specific legal, tax, and investment advice from a licensed professional.

Related posts

Leave a Comment